# ipamorelinsafe.com — full site as markdown > Editorial reading of the ipamorelin safety literature. Every page concatenated below in reading order. --- # Ipamorelin Safe — A safety ledger of what the literature actually says > An authored reading of the ipamorelin safety record: one short Phase 2 trial, FDA aggregation and immunogenicity concerns, no chronic human data, and a gray-market supply that flunks the basics. For research purposes only. The molecule is one of the cleanest-looking growth-hormone secretagogues ever characterized in a rat. The human record is shorter than most readers assume, and the supply chain is the part nobody talks about. ## What this site is — and is not Ipamorelin Safe is an independent editorial project that reads the ipamorelin literature the way a careful quarterly would read it: page by page, distinction by distinction, with the gaps drawn in as clearly as the findings. The publication is not a clinic. It is not a pharmacy. It does not employ clinicians, it does not write prescriptions, and it does not sell anything. The domain carries the word 'safe' because safety is the editorial subject — not because the editors are claiming the molecule is safe in any human use. Ipamorelin is not approved by the FDA, the EMA, or any other major regulator for any indication [5]. The largest human safety dataset in the published literature is one short Phase 2 trial in 114 postoperative bowel-resection patients [3]. Most of what is said online about ipamorelin's safety rests on that single seven-day intravenous study, on the preclinical selectivity work from 1998 [1], and on the structural absence of obvious red flags in the rat record. The honest reading is that absence-of-finding is not the same as evidence-of-absence — particularly when no chronic human study exists [4]. ## Why ipamorelin has the cleanest preclinical profile in its class The molecule is a synthetic pentapeptide — five amino acids, three of them unnatural, with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 [1]. It activates the growth hormone secretagogue receptor 1a (GHSR-1a) on pituitary somatotrophs, the same receptor endogenous ghrelin activates. In the foundational characterization, ipamorelin released growth hormone with potency comparable to GHRP-6 but did not raise adrenocorticotropic hormone or cortisol above the baseline produced by GHRH alone — even at exposures greater than two hundred times the GH ED50 [1]. That selectivity is the central safety claim made for ipamorelin against earlier growth-hormone-releasing peptides. It is real. It is also acute. The 1998 work was rat and swine pharmacology over short windows; the human PK/PD characterization that followed [2] was a single-dose study in eight male volunteers per dose level. Selectivity at the receptor is not a guarantee of safety in chronic exposure, and the downstream effects of repeatedly elevating growth hormone and insulin-like growth factor 1 — fluid retention, peripheral edema, arthralgia, carpal-tunnel-type symptoms, reduced peripheral insulin sensitivity — are class effects of any agent that meaningfully moves the GH axis [11]. They have not been quantified for ipamorelin in chronic human use because no chronic human ipamorelin study exists. ## The clinical record, in one paragraph The deepest published human PK/PD work on ipamorelin used five escalating fifteen-minute IV infusions in eight healthy male volunteers per dose group, modeled terminal half-life at approximately two hours, and reported acute tolerability at every dose level [2]. The largest published clinical trial randomized 114 adults undergoing open or laparoscopic bowel resection to 0.03 mg/kg IV ipamorelin twice daily versus placebo for up to seven days [3]; the primary efficacy endpoint missed (median time to first tolerated solid meal 25.3 hours in the ipamorelin arm versus 32.6 hours in placebo, P=0.15), and treatment-emergent adverse events occurred in 87.5 percent of the ipamorelin arm versus 94.8 percent of placebo — a comparable rate against a high surgical background. A second Helsinn-sponsored Phase 2 study (NCT01280344) completed but did not lead to a regulatory submission; the postoperative-ileus development program was discontinued, and ipamorelin has never advanced to Phase 3 for any indication [4]. That is the entire registered human record. ## The FDA's 2024 reading, briefly On October 29, 2024 the FDA's Pharmacy Compounding Advisory Committee reviewed both ipamorelin acetate and ipamorelin free base for inclusion in the 503A Bulks Regulation. The agency recommended against inclusion of either form [5]. The briefing record cites specific concerns about peptide aggregation in injectable subcutaneous formulations, the immunogenicity implications of aggregation, and the difficulty of characterizing impurities in a peptide built from unnatural amino acids (Aib, D-2-Nal, D-Phe) [6]. The same regulatory record references a serious adverse event including death in a development-stage IV protocol — a route- and protocol-specific event, but on the record nonetheless [7]. The practical consequence is that there is no FDA-sanctioned compounding pathway for ipamorelin in the United States as of late 2024. Its removal from the interim 503B Category 2 list, effective September 27, 2024, was a procedural consequence of a withdrawn nomination — not an FDA endorsement of safety [5]. ## How to read this site Each content page below is a chapter in the same ledger. /research walks the literature in the order it was published. /dosage describes the doses that have actually appeared in published rodent and human protocols, in research context only. /faq answers the questions that recur in search behavior around 'ipamorelin safety.' /references is the full numbered citation list with DOIs and PubMed links. /about explains what this publication is and is not. /contact tells you how to write to the editors. Nothing on this site is medical advice, a recommendation, or an endorsement. The editorial position is that the ipamorelin literature deserves a careful authored reading and that the most honest version of that reading is also the most useful one. ## References [1] Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. [2] Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. [3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. [4] Helsinn Therapeutics (US), Inc. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. ClinicalTrials.gov NCT01280344. 2014. [5] U.S. FDA. FDA Briefing Document, PCAC Meeting (October 29, 2024) — Ipamorelin Acetate and Ipamorelin (free base) review for 503A Bulks Regulation. 2024. [6] U.S. FDA / Lexology / Holt Law summaries. FDA Briefing Document on Ipamorelin (PCAC, October 2024) — aggregation, immunogenicity, and unnatural amino acid characterization concerns. 2024. [7] U.S. FDA; Hone Health and ProPublica summaries. FDA Briefing Document on Ipamorelin (PCAC, October 2024) — serious adverse event reference. 2024. [11] Buscail E, Deraison C. Postoperative ileus: A pharmacological perspective. British Journal of Pharmacology. 2022;179(13):3283-3305. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor. --- # The ipamorelin research literature, read in order > A page-by-page editorial walk through the ipamorelin literature: 1998 selectivity, 1999 human PK/PD, the 2014 Phase 2, the 2024 FDA review, and the chronic-exposure questions that remain open. From the 1998 selectivity characterization to the 2024 FDA briefing — the published record, paced by what each study was and was not designed to answer. ## 1998: The selectivity claim, and what it does and does not cover The foundational paper is Raun et al., 1998, in the European Journal of Endocrinology [1]. The investigators characterized ipamorelin across rat pituitary cells, anesthetized rats, and conscious swine. The headline finding was selectivity: ipamorelin released growth hormone with potency comparable to GHRP-6, yet at exposures greater than two hundred times the GH ED50 it did not raise adrenocorticotropic hormone, cortisol, prolactin, follicle-stimulating hormone, luteinizing hormone, or thyroid-stimulating hormone above the baseline produced by GHRH alone [1]. That cleanness against the broader pituitary axis is the original — and still most-cited — safety claim made for ipamorelin against earlier growth-hormone-releasing peptides. The work was acute. The dosing windows were short. The species were rat and swine. The 1998 paper was never designed to answer chronic-exposure questions, and the editorial reading is that selectivity at the receptor, as described in this paper, is a narrow and useful fact — not a general license. Downstream effects of repeatedly elevating growth hormone and insulin-like growth factor 1 are governed by different biology than the immediate pituitary release the 1998 paper measured. ## 1999: The human PK/PD work, in eight men per dose group Gobburu et al., 1999, in Pharmaceutical Research, remains the deepest published characterization of ipamorelin pharmacology in humans [2]. The investigators gave five escalating fifteen-minute intravenous infusions — 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg — to eight healthy male volunteers per dose group, then fit a population PK/PD model to the GH response. Terminal half-life came out at approximately two hours. Clearance was 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg. The SC50 for half-maximal GH stimulation was 214 nmol/L, and the maximum GH production rate was 694 mIU/L/h. GH peaked at roughly 0.67 hours after dosing and declined exponentially toward baseline within hours [2]. The study reported the molecule as tolerated at all dose levels. It also has limits that the abstract does not advertise: eight subjects per dose group, men only, single dose, healthy. It tells the reader almost nothing about repeat dosing in any population, nothing about women, nothing about the elderly, and nothing about subjects with any comorbidity that might interact with the GH axis. Every estimate later quoted as the half-life of ipamorelin in humans traces back to this single study. ## 2014: The Phase 2 postoperative-ileus trial The largest published human ipamorelin trial is Beck et al., 2014, in the International Journal of Colorectal Disease [3]. It enrolled 114 adults undergoing open or laparoscopic bowel resection and randomized them to 0.03 mg/kg IV ipamorelin twice daily versus placebo for up to seven days. The hypothesis was that a ghrelin-receptor agonist might shorten postoperative ileus — the period of impaired gastrointestinal motility that follows abdominal surgery. The primary efficacy endpoint missed: median time to first tolerated solid meal was 25.3 hours in the ipamorelin arm versus 32.6 hours in placebo, P=0.15. Treatment-emergent adverse events occurred in 87.5 percent of the ipamorelin arm and 94.8 percent of the placebo arm [3]. A second Helsinn-sponsored study, NCT01280344, completed but did not lead to a regulatory submission [4]. AdisInsight and review summaries describe the discontinuation as driven by lack of efficacy rather than a safety signal [12]. The consequence for the safety record is the same either way: no Phase 3, no large or long-duration human safety database, no post-marketing surveillance, no pharmacovigilance file. Ipamorelin's published human safety database is one short perioperative IV trial — and the high background adverse-event rate of the surgical setting makes detection of drug-attributable signals harder, not easier. ## The mechanism the rat models do show Beyond the pituitary, the rodent literature attaches several mechanistic observations to ipamorelin that are worth keeping in the ledger. In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90, and 450 micrograms per day (TID for 15 days) produced dose-dependent increases in longitudinal bone growth rate — from 42 to 44, 50, and 52 microns per day, respectively — without a measurable change in total IGF-1 at the timepoints sampled [15]. Chronic SC dosing in young female rats stimulated body weight gain and preserved in-vitro GH release from cultured pituitary cells of treated animals, suggesting minimal tachyphylaxis in that model and dosing pattern [16]. In ex vivo pancreatic tissue from normal and streptozotocin-diabetic rats, ipamorelin at concentrations from 10^-12 to 10^-6 M produced direct insulinotropic activity that was attenuated by L-type calcium channel block, alpha-2-adrenergic block, and a cholinergic-adrenergic blocker cocktail [9]. That finding is mechanistically important — it establishes that ipamorelin is not strictly pituitary-selective at the tissue level. The most recent published in-vivo work, a 2024 ferret study, showed intraperitoneal ipamorelin reduced delayed-phase cisplatin-induced body weight loss by approximately 24 percent without affecting cisplatin-induced emesis at the doses tested [13]; the seventy-two-hour window provides no information on chronic exposure. ## The 2024 FDA reading: aggregation, immunogenicity, unnatural amino acids The October 29, 2024 Pharmacy Compounding Advisory Committee meeting is the most recent regulatory event in ipamorelin's record. The FDA reviewed both ipamorelin acetate and ipamorelin free base for inclusion in the 503A Bulks Regulation and recommended against inclusion of either form [5]. The briefing record focuses on three categories of concern. First, the molecule contains three unnatural amino acids (Aib at position 1, D-2-naphthylalanine at position 3, D-phenylalanine at position 4). The FDA briefing notes that "generally less is known about the safety and biological properties of peptides that contain unnatural amino acids," including the structure and chromatographic behavior for purification of such residues and any impact on aggregation propensity [6]. Second, the agency identifies aggregation in injectable subcutaneous formulations as a CMC-level safety concern with direct immunogenicity implications [6]. Third, the briefing record references a serious adverse event including death in a development-stage IV protocol; the event is route- and protocol-specific but is part of the regulatory record [7]. The procedural outcome was that ipamorelin acetate was removed from the interim 503B Category 2 list effective September 27, 2024, on the basis of a withdrawn nomination — not an endorsement of safety [5]. The compound sits outside any FDA-sanctioned compounding pathway as of late 2024. ## Class signals worth keeping in the ledger Two class-level findings sit alongside the ipamorelin-specific record and inform any honest safety reading. First, a 28-day rat dosing study of a different GHSR-1a agonist (GSK894281) at 0.3, 1, 10, and 60 mg/kg/day found dose-dependent myocardial degeneration and necrosis on light and electron microscopy, with elevated serum cardiac troponin I and fatty acid-binding protein 3 [10]. The study was conducted specifically because cardiovascular injury had been observed in longer-term dosing across this receptor class. Ipamorelin itself has not been tested chronically in published cardiovascular safety pharmacology at comparable exposures. That absence is the point — it is the kind of finding that long-duration ipamorelin work would specifically need to rule out before any chronic human use could be considered. Second, recombinant growth hormone — well-characterized clinically — has a documented adverse-event signature that includes fluid retention, peripheral edema, arthralgia, and carpal-tunnel-type symptoms attributed to interstitial fluid accumulation and tissue response to GH [11]. Acute ipamorelin trials were too short to capture this signature. Chronic SC dosing in non-clinical settings is, by mechanism, expected to reproduce some part of it. A systematic review of ghrelin and ghrelin-agonist studies found mostly null or inverse associations between ghrelin signaling and cancer risk and progression in animal models [17] — receptor-level reassurance that coexists with the unmeasured question of what chronic IGF-1 elevation looks like in ipamorelin-exposed humans, because no chronic ipamorelin human study has measured it. ## The supply chain is part of the safety reading The dominant real-world ipamorelin safety risk in 2024-2026 may not be the molecule itself but the vial. Forensic pharmacovigilance analysis of gray-market injectable peptides documents systematic quality failures: residual industrial synthesis solvents (tetrahydrofuran detected in 100 percent of one seized Belgian sample set), heavy metals exceeding pharmaceutical safety thresholds (arsenic or lead in roughly 26 percent of samples), endotoxin levels exceeding safety thresholds in approximately 65 percent of online peptide samples, and label-claim purity as low as a small single-digit percentage in some products [14]. Ipamorelin participates in the same supply channels. A molecule with a clean acute pharmacology, administered as an endotoxin-contaminated, heavy-metal-laden, mis-identified injection, is not a safe injection. That is a product-quality safety question, distinct from the receptor pharmacology, and it is the gap the FDA's 2024 review and ongoing peptide enforcement environment [5][6] are most directly addressing. ## References [1] Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. [2] Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. [3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Phase 2 ipamorelin RCT in postoperative ileus. International Journal of Colorectal Disease. 2014;29(12):1527-1534. [4] Helsinn Therapeutics (US), Inc. Ipamorelin vs Placebo for Recovery of GI Function. ClinicalTrials.gov NCT01280344. 2014. [5] U.S. FDA. PCAC Briefing Document (October 29, 2024) — Ipamorelin Acetate and Ipamorelin (free base) review for 503A Bulks Regulation. 2024. [6] U.S. FDA / Lexology / Holt Law summaries. FDA Briefing Document on Ipamorelin (PCAC, October 2024) — aggregation, immunogenicity, unnatural amino acids. 2024. [7] U.S. FDA; Hone Health and ProPublica summaries. FDA Briefing Document on Ipamorelin — serious adverse event reference. 2024. [9] Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters. 2004;25(6):403-406. [10] Stokes AH et al. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist. Toxicologic Pathology. 2015;43(5):709-721. [11] Buscail E, Deraison C. Postoperative ileus: A pharmacological perspective. British Journal of Pharmacology. 2022;179(13):3283-3305. [12] Mosinska P et al. Future Treatment of Constipation-associated Disorders. J Neurogastroenterol Motil. 2017;23(2):171-179. [13] Tu L et al. Anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets. Physiology & Behavior. 2024;284:114631. [14] Preventive Medicine Daily editorial / pharmacovigilance review. Gray-Market Peptides from China. 2024. [15] Johansen PB et al. Ipamorelin induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. [16] Lall S et al. Chronic in vivo Ipamorelin treatment in young female rats. Growth Hormone & IGF Research. 2003;13(2-3):126-136. [17] Lin TC, Hsiao M. Is there an effect of ghrelin/ghrelin analogs on cancer? Endocrine-Related Cancer. 2017;24(7):C45-C50. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor. --- # Ipamorelin dosing in the published research record > The doses that have actually appeared in published rodent and human ipamorelin protocols, with half-life, routes, and the chronic-exposure gap clearly drawn. Research context only. A ledger of the rodent and human protocols that anchor every ipamorelin dose number in circulation — and a clear note on the dosing questions the record does not answer. ## A note on what this page is This page describes the doses ipamorelin has been administered at in published research protocols. It does not recommend a dose for any human use. Ipamorelin is not approved for human consumption [5]; the only documented human exposure in a registered clinical trial used the intravenous route in a perioperative setting [3]. Subcutaneous dosing in non-clinical use sits outside any approved pathway, and the chronic safety questions that would be required to evaluate it have never been answered in any published human study [4]. Every dose figure below is reported with the species, route, duration, and study citation that produced it. The point of laying them out together is to show what the literature is — a series of short, narrowly-scoped protocols, mostly in rodents, that together do not add up to a chronic human safety database. ## Human intravenous doses (the entire registered record) Two registered human-dosing protocols dominate the published human ipamorelin literature. Gobburu et al., 1999 (PK/PD characterization): five escalating fifteen-minute IV infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg, given to eight healthy male volunteers per dose group [2]. Reported terminal plasma half-life approximately two hours; GH peak roughly 0.67 hours after dosing; rapid exponential decline to baseline within hours. Reported as tolerated at every dose level — but in eight men per group, single dose only. Beck et al., 2014 (Phase 2 RCT in postoperative ileus): 0.03 mg/kg IV ipamorelin twice daily for up to seven days, against placebo, in 114 adults recovering from open or laparoscopic bowel resection [3]. Treatment-emergent adverse events occurred in 87.5 percent of the ipamorelin arm versus 94.8 percent of placebo. Primary efficacy endpoint missed. The trial is the longest registered human exposure to ipamorelin in the published record — seven days, IV, in a perioperative setting [3]. A second Helsinn-sponsored Phase 2 study (NCT01280344) completed but did not lead to a regulatory submission [4]. No human study of subcutaneous ipamorelin appears in the registered record. ## Rodent subcutaneous and intravenous doses The rodent literature is broader and shorter-window than the human literature. Notable published protocols include: Johansen et al., 1999: 18, 90, and 450 micrograms per day, divided three times per day, subcutaneously, for 15 days in adult female Sprague-Dawley rats. Outcome: dose-dependent increase in longitudinal bone growth rate from 42 microns per day in vehicle to 44, 50, and 52 microns per day at the three dose levels, P<0.0001. Total IGF-1 unchanged at the timepoints measured [15]. Lall et al., 2003: chronic SC ipamorelin in young female rats; specific dose not fully extractable from the abstract. Outcome: body weight gain and sustained in-vitro GH release from cultured pituitary cells of treated animals, suggesting minimal tachyphylaxis in this model and dosing pattern [16]. Adeghate and Ponery, 2004: in-vitro pancreatic tissue from normal and streptozotocin-diabetic rats incubated with ipamorelin at concentrations from 10^-12 to 10^-6 M. Outcome: direct insulinotropic activity attenuated by L-type calcium channel block, alpha-2-adrenergic block, and a cholinergic-adrenergic blocker cocktail [9]. Tu et al., 2024: intraperitoneal ipamorelin in ferrets; specific dose not fully specified in the abstract. Outcome: reduction in delayed-phase cisplatin-induced weight loss by approximately 24 percent versus control over a 72-hour window, with no effect on cisplatin-induced emesis [13]. ## Half-life and pharmacokinetic notes The terminal plasma half-life of ipamorelin in healthy male volunteers receiving a fifteen-minute IV infusion was approximately two hours [2]. Clearance was 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg, SC50 for half-maximal GH stimulation 214 nmol/L [2]. GH peaked at roughly 0.67 hours after dosing and declined exponentially toward baseline within hours. This is the only published human PK/PD model. SC pharmacokinetics in humans have not been characterized in any registered ipamorelin trial. The two-hour half-life and short GH peak window are the basis for the intermittent multi-daily dosing patterns that appear in rodent protocols [15][16] and in non-clinical use discussions in review literature. The mechanistic rationale is to approximate the body's natural pulsatile GH release pattern rather than to produce a continuous receptor-occupancy signal, which is the dosing pattern that has been associated with tachyphylaxis in the broader ghrelin-agonist class [16]. Whether intermittent SC ipamorelin dosing avoids tachyphylaxis in chronic human use is an open question. ## Stability, formulation, and the FDA's CMC concerns Lyophilized ipamorelin is reported stable refrigerated. Reconstituted solutions in laboratory protocols are typically described as having short shelf life. The FDA's October 2024 PCAC review identified two manufacturing-level concerns that sit on top of any dose discussion. The first is aggregation propensity in injectable subcutaneous formulations, which has direct immunogenicity implications [6]. The second is the structural difficulty of impurity characterization given the three unnatural amino acids in the sequence (Aib, D-2-Nal, D-Phe), each of which complicates purification chemistry and chromatographic behavior [6]. These are not dose questions in the pharmacological sense; they are quality questions about the product the dose is delivered in. Forensic analysis of gray-market injectable peptides has documented residual industrial synthesis solvents, heavy metals exceeding pharmaceutical thresholds, and endotoxin levels exceeding safety thresholds in a substantial majority of sampled products [14]. The molecule's intrinsic dose-response is one part of the picture. The vial it arrives in is another part. The two cannot be cleanly separated in any real-world risk assessment. ## References [2] Gobburu JV et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. [3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Phase 2 ipamorelin RCT in postoperative ileus. International Journal of Colorectal Disease. 2014;29(12):1527-1534. [4] Helsinn Therapeutics (US), Inc. Ipamorelin vs Placebo for Recovery of GI Function. ClinicalTrials.gov NCT01280344. 2014. [5] U.S. FDA. PCAC Briefing Document (October 29, 2024) — Ipamorelin Acetate / free base review for 503A. 2024. [6] U.S. FDA / Lexology / Holt Law summaries. FDA Briefing Document on Ipamorelin — aggregation, immunogenicity, unnatural amino acids. 2024. [9] Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters. 2004;25(6):403-406. [13] Tu L et al. Anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets. Physiology & Behavior. 2024;284:114631. [14] Preventive Medicine Daily editorial / pharmacovigilance review. Gray-Market Peptides from China. 2024. [15] Johansen PB et al. Ipamorelin induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. [16] Lall S et al. Chronic in vivo Ipamorelin treatment in young female rats. Growth Hormone & IGF Research. 2003;13(2-3):126-136. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor. --- # Ipamorelin safety FAQ — answers to the questions readers actually ask > Direct, cited answers to the recurring questions about ipamorelin safety: the Phase 2 trial adverse events, the FDA's 2024 review, the chronic-exposure gap, glycemic effects, gray-market product quality, and how it compares to GHRP-6 and GHRP-2. ## Is ipamorelin safe based on what the research actually shows? The honest answer is that the research shows acute tolerability in narrow, short, registered protocols — and a striking absence of any chronic human safety data. The 1998 Raun characterization established a clean selectivity profile against ACTH, cortisol, prolactin, and other pituitary hormones at exposures greater than 200 times the GH ED50 in rats and swine [1]. The 1999 Gobburu single-dose human PK/PD study reported the molecule as tolerated in eight male volunteers per dose group [2]. The 2014 Beck Phase 2 trial reported treatment-emergent adverse events in 87.5 percent of the ipamorelin arm versus 94.8 percent of placebo across seven days of IV dosing in postoperative bowel-resection patients [3]. Beyond that, the published human safety record stops. There is no Phase 3 [4], no chronic SC human study, no post-marketing surveillance, and the FDA's October 2024 review explicitly identified aggregation, immunogenicity, and impurity-characterization concerns at the manufacturing level [5][6]. 'Safe' is not the right one-word summary of that record; 'acutely tolerated in narrow contexts, chronically uncharacterized' is closer. ## What adverse events were reported in the ipamorelin Phase 2 trial? Beck et al., 2014, reported treatment-emergent adverse events in 87.5 percent of the ipamorelin arm (0.03 mg/kg IV twice daily for up to seven days) versus 94.8 percent of the placebo arm, in 114 adults recovering from open or laparoscopic bowel resection [3]. No statistically significant ipamorelin-specific adverse event signal was identified at this dose and duration. The trial did not, however, meet its primary efficacy endpoint: median time to first tolerated solid meal was 25.3 hours in the ipamorelin arm versus 32.6 hours in placebo, P=0.15 [3]. Two contextual notes apply. First, the perioperative setting produces a high background adverse-event rate — 94.8 percent in placebo limits the ability to detect drug-attributable signals. Second, this trial is the largest published human safety dataset for ipamorelin in any setting. The independent 2017 review by Mosinska and colleagues concluded that ipamorelin in this trial was well tolerated but did not produce statistically significant motility effects [12]. ## Why did the FDA flag ipamorelin in 2024, and what does the briefing document say? On October 29, 2024 the FDA's Pharmacy Compounding Advisory Committee reviewed both ipamorelin acetate and ipamorelin free base for inclusion in the 503A Bulks Regulation. The agency recommended against inclusion of either form [5]. The briefing record cites three categories of concern. First, the molecule contains three unnatural amino acids — Aib (alpha-aminoisobutyric acid), D-2-naphthylalanine, and D-phenylalanine — and the FDA explicitly noted that "generally less is known about the safety and biological properties of peptides that contain unnatural amino acids," including the structure and chromatographic behavior for purification of such residues and any impact on aggregation propensity [6]. Second, the agency identified aggregation in injectable subcutaneous formulations as a CMC-level safety concern with direct immunogenicity implications [6]. Third, the briefing record references a serious adverse event including death in a development-stage IV protocol [7]. Ipamorelin acetate was subsequently removed from the interim 503B Category 2 list effective September 27, 2024, on the procedural basis of a withdrawn nomination — not an FDA endorsement of safety [5]. ## What does 'no chronic human safety data' mean in practice? It means exactly what it says: no published or registered human ipamorelin study has dosed beyond seven days. The longest human exposure on the record is the seven-day intravenous Phase 2 in postoperative bowel-resection patients [3]. Everything beyond that is rodent data, mostly over short windows. The 1999 human PK/PD work was single-dose [2]. The 2014 trial was seven days IV. The 2024 ferret study was a 72-hour window [13]. No registered human study has characterized subcutaneous ipamorelin pharmacokinetics, no study has measured chronic IGF-1 dynamics in humans, no study has quantified fluid retention or peripheral edema or carpal-tunnel-type symptoms in chronic ipamorelin exposure, and no manufacturer is obligated to maintain a pharmacovigilance file because the compound has never been approved [18]. The practical consequence is that questions about long-term safety — cardiovascular effects, insulin sensitivity, cancer risk via chronic IGF-1 elevation, immunogenicity over months of repeated injection — cannot be answered from the published record. ## Has anyone died from ipamorelin in a clinical study? The FDA's October 2024 PCAC briefing record references a serious adverse event including death in a development-stage IV ipamorelin protocol [7]. The event was reported in a specific experimental IV-infusion setting and is described in regulatory-summary coverage as outside the typical small subcutaneous dosing range described in non-clinical research literature. The relevant editorial point is not that the molecule has a defined mortality signal — it does not, at the resolution the published record allows — but that the regulatory record contains a documented serious adverse event in an ipamorelin study, which is sufficient to invalidate the blanket marketing claim that 'no serious adverse events have ever been reported' [7]. The 2014 Beck Phase 2 trial in 114 postoperative patients did not report a drug-attributable mortality signal at 0.03 mg/kg IV twice daily for up to seven days [3]. ## Does ipamorelin cause insulin resistance or affect blood sugar? Two mechanistic threads converge on this question, and neither has been resolved in chronic human use. First, growth hormone itself opposes peripheral insulin action at chronic elevation — a well-characterized class effect of any agent that meaningfully raises GH and IGF-1 [11]. Acute ipamorelin trials were too short to capture this effect, and no chronic human ipamorelin study has been done [4]. Second, Adeghate and Ponery, 2004, demonstrated that ipamorelin has direct insulinotropic activity in ex vivo pancreatic tissue at concentrations from 10^-12 to 10^-6 M, with the effect attenuated by L-type calcium channel block, alpha-2-adrenergic block, and a cholinergic-adrenergic blocker cocktail [9]. That finding establishes ipamorelin is not strictly pituitary-selective at the tissue level. The combination — direct pancreatic insulin release plus indirect GH-mediated reduction in peripheral insulin sensitivity over time — means glycemic effects are biologically plausible and bidirectional, particularly in subjects with disordered glucose handling. The magnitude in chronic human use is unmeasured. ## Can ipamorelin cause water retention, edema, or carpal-tunnel-type symptoms like recombinant GH? Mechanistically, yes — any agent that meaningfully elevates GH and IGF-1 carries the class signature of fluid retention, peripheral edema, arthralgia, and carpal-tunnel-type symptoms attributed to interstitial fluid accumulation and tissue response to GH [11]. Recombinant GH is well-characterized for this signature. The relevant qualifier is that none of these effects have been quantified in chronic ipamorelin human use, because no chronic ipamorelin human study exists [4]. The 1999 single-dose study and the seven-day 2014 Phase 2 trial [2][3] were too short to capture the dose-dependent, generally reversible class signature that emerges with sustained GH elevation. By mechanism, chronic SC ipamorelin in non-clinical settings is expected to reproduce some part of this signature; what is missing is the published trial that would quantify it. ## Is the CJC-1295 + ipamorelin combination safety established in humans? No. The combination is discussed in non-peer-reviewed literature on the rationale that a GHRH-receptor agonist (CJC-1295) and a GHSR-1a agonist (ipamorelin) act on distinct but converging pituitary pathways and may produce additive or supra-additive GH pulses in animal models. No rigorous controlled human trial of the specific CJC-1295 + ipamorelin combination appears in peer-reviewed indexes. Safety claims for the combination rest on the separate single-compound records — neither of which includes chronic human safety data — plus community report data, which is not pharmacovigilance. Tesamorelin is sometimes discussed alongside ipamorelin in review literature as a representative GHRH analog, and combination safety in humans has not been characterized for that pairing either. ## How risky is gray-market or research-chemical ipamorelin from a product-quality standpoint? This is arguably the dominant real-world ipamorelin safety risk in 2024-2026, independent of the molecule's intrinsic pharmacology. Forensic analysis of gray-market injectable peptides has documented residual industrial synthesis solvents (tetrahydrofuran detected in 100 percent of one seized Belgian sample set), heavy metals exceeding pharmaceutical safety thresholds (arsenic or lead in roughly 26 percent of samples), endotoxin levels exceeding safety thresholds in approximately 65 percent of online peptide samples, and label-claim purity as low as a small single-digit percentage in some products [14]. Ipamorelin sits in the same supply channels. The FDA's October 2024 review of compounded ipamorelin acetate also identified aggregation propensity and impurity characterization as specific safety concerns at the manufacturing level [6], and the agency has pursued an active enforcement environment around peptide vendors in 2024-2025. A clean acute pharmacology administered as an endotoxin-contaminated, heavy-metal-laden, mis-identified injection is not a safe injection. ## Does ipamorelin develop tolerance (tachyphylaxis) over time? Tachyphylaxis is documented for the broader ghrelin-agonist class with continuous-infusion regimens, with desensitization appearing within days in animal and human studies. The most relevant ipamorelin-specific data are from Lall et al., 2003, which dosed young female rats chronically SC and harvested pituitary cells for in-vitro GH release testing; the cultured cells from treated animals continued to release GH, suggesting minimal tachyphylaxis in that model and dosing pattern [16]. That is reassuring but limited: intermittent SC dosing in rodents over a limited window does not establish absence of tachyphylaxis in chronic human use, particularly given that no chronic human ipamorelin study has measured GH or IGF-1 dynamics across months of repeated exposure. The mechanistic argument for pulsatile intermittent dosing — that it approximates the body's natural GH release pattern — is the rationale most often offered against tachyphylaxis concerns, but it has not been tested in a registered human protocol. ## Why aren't there Phase 3 ipamorelin trials, and what does that mean for the safety record? Ipamorelin was developed by Novo Nordisk and later licensed to Helsinn Therapeutics for postoperative ileus. Two registered Helsinn Phase 2 studies were conducted: NCT00672074, published as Beck et al., 2014 [3], and NCT01280344 [4]. The first missed its primary efficacy endpoint; the second completed but did not lead to a regulatory submission. AdisInsight and independent review-literature summaries describe the discontinuation as driven by lack of efficacy rather than a safety signal [12]. The consequence for the safety record is the same either way. No Phase 3 means no large or long-duration safety database in any population. No marketing authorization means no manufacturer is obligated to maintain a pharmacovigilance file [18]. The narrative review by Ishida and colleagues, 2020, places ipamorelin as a prototype that informed later clinical-stage compounds (anamorelin in oncology cachexia, macimorelin in diagnostic GH stimulation) but notes ipamorelin itself has no current marketing authorization [18] — a structural feature of its safety story. ## How does ipamorelin's safety profile compare to GHRP-6 and GHRP-2? Ipamorelin's central selectivity claim against GHRP-6 and GHRP-2 is that it releases growth hormone with comparable potency to GHRP-6 but does not raise ACTH, cortisol, prolactin, FSH, LH, or TSH above the baseline produced by GHRH alone, even at exposures greater than 200 times the GH ED50 — the foundational characterization by Raun et al., 1998 [1]. GHRP-6 and GHRP-2 are documented to produce more measurable cortisol and prolactin co-release in research settings, and that distinction is the basis for ipamorelin being described as 'cleaner' within the GHRP class. The qualifier is the same one that applies elsewhere on this site: the selectivity comparison rests on acute preclinical pharmacology, and none of the three compounds — ipamorelin, GHRP-6, or GHRP-2 — has a chronic human safety database. The 'cleaner' description is accurate for the receptor pharmacology that was measured; it is not a general claim about safety in chronic exposure that any of these compounds have ever been tested in. ## Is ipamorelin banned in sport? Yes. Ipamorelin appears on the World Anti-Doping Agency Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), subsection 2.4 (Growth Hormone Releasing Factors), banned at all times in and out of competition [8]. The 2026 WADA list strengthens the language to cover 'any substance with a similar chemical structure or similar biological effect' [8]. Use by athletes subject to WADA jurisdiction is an anti-doping rule violation. The WADA categorization is not, strictly speaking, a safety judgment — it is a sport-fairness regulation — but the S2 subcategory also reflects the regulator's view that ipamorelin and similar agents meaningfully manipulate the GH and IGF-1 axis, which is the same axis from which the chronic-exposure safety concerns derive. ## References [1] Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. [2] Gobburu JV et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. [3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Phase 2 ipamorelin RCT in postoperative ileus. International Journal of Colorectal Disease. 2014;29(12):1527-1534. [4] Helsinn Therapeutics (US), Inc. Ipamorelin vs Placebo for Recovery of GI Function. ClinicalTrials.gov NCT01280344. 2014. [5] U.S. FDA. PCAC Briefing Document (October 29, 2024) — Ipamorelin Acetate / free base review for 503A. 2024. [6] U.S. FDA / Lexology / Holt Law summaries. FDA Briefing Document on Ipamorelin — aggregation, immunogenicity, unnatural amino acids. 2024. [7] U.S. FDA; Hone Health / ProPublica summaries. FDA Briefing Document on Ipamorelin — serious adverse event reference. 2024. [8] World Anti-Doping Agency. The 2026 Prohibited List, Section S2.2.4. 2026. [9] Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters. 2004;25(6):403-406. [11] Buscail E, Deraison C. Postoperative ileus: A pharmacological perspective. British Journal of Pharmacology. 2022;179(13):3283-3305. [12] Mosinska P et al. Future Treatment of Constipation-associated Disorders. J Neurogastroenterol Motil. 2017;23(2):171-179. [13] Tu L et al. Anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets. Physiology & Behavior. 2024;284:114631. [14] Preventive Medicine Daily editorial / pharmacovigilance review. Gray-Market Peptides from China. 2024. [16] Lall S et al. Chronic in vivo Ipamorelin treatment in young female rats. Growth Hormone & IGF Research. 2003;13(2-3):126-136. [18] Ishida J et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor. --- # References — the ipamorelin literature cited on this site > Numbered citation list with DOIs and PubMed links for every ipamorelin study referenced on Ipamorelin Safe — from the 1998 selectivity characterization to the 2024 FDA briefing. ## How to read this list The numbered citations below correspond to the bracketed inline markers across the site. Each entry includes the journal of record, year, volume and pages where applicable, DOI when available, and a PubMed or primary-source URL. Outbound links here are intentional and lead only to legitimate primary sources — PubMed, PubMed Central, ClinicalTrials.gov, the FDA, the World Anti-Doping Agency, and peer-reviewed journals. No portfolio interlinks appear here or anywhere on this site. ## Numbered citations [1] Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. DOI 10.1530/eje.0.1390552. https://pubmed.ncbi.nlm.nih.gov/9849822/ [2] Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. DOI 10.1023/A:1018955126402. https://pubmed.ncbi.nlm.nih.gov/10496658/ [3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. DOI 10.1007/s00384-014-2030-8. https://pubmed.ncbi.nlm.nih.gov/25331030/ [4] Helsinn Therapeutics (US), Inc. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. ClinicalTrials.gov registry record NCT01280344. 2014. https://clinicaltrials.gov/study/NCT01280344 [5] U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting (October 29, 2024) — Ipamorelin Acetate and Ipamorelin (free base) review for 503A Bulks Regulation. 2024. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee-pcac/2024-meeting-materials-pharmacy-compounding-advisory-committee [6] U.S. Food and Drug Administration / Lexology summary / Holt Law summary. FDA Briefing Document on Ipamorelin (PCAC, October 2024) — aggregation, immunogenicity, and unnatural amino acid characterization concerns. 2024. https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d [7] U.S. Food and Drug Administration; secondary summary by Hone Health and ProPublica. FDA Briefing Document on Ipamorelin (PCAC, October 2024) — serious adverse event reference. 2024. https://www.propublica.org/article/peptide-safety-fda-compounding-pharmacies [8] World Anti-Doping Agency. World Anti-Doping Code International Standard — The 2026 Prohibited List, Section S2.2.4 (Growth Hormone Releasing Factors). 2026. https://www.wada-ama.org/en/prohibited-list [9] Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters. 2004;25(6):403-406. https://pubmed.ncbi.nlm.nih.gov/15665801/ [10] Stokes AH, Falls JG, Yoon L, Cariello N, Faiola B, Colton HM, Jordan HL, Berridge BR. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist. Toxicologic Pathology. 2015;43(5):709-721. DOI 10.1177/0192623315573029. https://pubmed.ncbi.nlm.nih.gov/25722321/ [11] Buscail E, Deraison C. Postoperative ileus: A pharmacological perspective. British Journal of Pharmacology. 2022;179(13):3283-3305. DOI 10.1111/bph.15800. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15800 [12] Mosinska P, Zatorski H, Storr M, Fichna J. Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists. Journal of Neurogastroenterology and Motility. 2017;23(2):171-179. DOI 10.5056/jnm16183. https://pmc.ncbi.nlm.nih.gov/articles/PMC5383112/ [13] Tu L, Lu Z, Ngan MP, Lam FFY, Giuliano C, Lovati E, Pietra C, Rudd JA. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & Behavior. 2024;284:114631. DOI 10.1016/j.physbeh.2024.114631. https://pubmed.ncbi.nlm.nih.gov/39032817/ [14] Preventive Medicine Daily editorial / pharmacovigilance review. Gray-Market Peptides from China: A Pharmacovigilance Analysis of Safety Risks and Consumer Protection. 2024. https://www.preventivemedicinedaily.com/drug-safety/gray-market-peptides-safety-risks/ [15] Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. DOI 10.1054/ghir.1999.9998. https://pubmed.ncbi.nlm.nih.gov/10373343/ [16] Lall S, Balthasar N, Carmignac D, Magoulas C, Sesay A, Houston P, Robinson IC. Chronic in vivo Ipamorelin treatment stimulates body weight gain and growth hormone (GH) release in vitro in young female rats. Growth Hormone & IGF Research. 2003;13(2-3):126-136. DOI 10.1016/S1096-6374(03)00018-8. https://www.sciencedirect.com/science/article/abs/pii/S1096637403000188 [17] Lin TC, Hsiao M. Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review. Endocrine-Related Cancer. 2017;24(7):C45-C50. DOI 10.1530/ERC-16-0489. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064755/ [18] Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. DOI 10.1002/rco2.9. https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9 --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor. --- # About Ipamorelin Safe — independent editorial publisher > Ipamorelin Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on ipamorelin. Not a clinic, not a pharmacy. For research purposes only. Authored, hand-bound, and deliberately careful — what the published research documents, and what it does not. ## What this publication is Ipamorelin Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on ipamorelin. The publication is not a clinic. It does not employ clinicians and it does not provide medical advice. It does not manufacture, sell, or distribute any product. Its work is editorial commentary on publicly available science. The word 'safe' in the domain name is editorial framing — the site's subject is safety, the careful authored question of what the literature does and does not document about how the molecule behaves in research settings. It is not a marketing claim that the molecule is safe for any human use. The 1998 selectivity characterization in rats and swine [1], the 1999 single-dose human PK/PD work in eight male volunteers per dose group [2], the 2014 Phase 2 trial in 114 postoperative patients over seven days IV [3], and the FDA's October 2024 review of ipamorelin for inclusion in the 503A Bulks Regulation [5] are the central documents this publication reads. ## Editorial standards Every quantitative claim on this site is sourced to a specific entry in the references list. Dose values, half-life numbers, study sample sizes, adverse event percentages, and regulatory dates all carry a bracketed numeric citation that resolves to a peer-reviewed publication, a ClinicalTrials.gov record, or an FDA briefing document. The publication does not invent research. If a claim is not in the cited literature, it does not appear on the site. The publication does not recommend doses, propose protocols, or describe non-clinical use as if it were clinical practice. Where the literature is silent on a question — and on ipamorelin, the literature is silent on most chronic-exposure questions — that silence is named explicitly rather than papered over with reassurance. The editorial voice is intentionally authored. The design language is that of a hand-bound quarterly. The goal is the careful, paced reading that a peptide with this much marketing noise around it actually deserves. ## What this publication is not Ipamorelin Safe is not a clinic, not a pharmacy, not a telehealth service, and not a vendor. It does not connect readers with clinicians or with suppliers. It does not sell ipamorelin, ipamorelin combinations, reconstitution materials, or any other product. It does not write prescriptions, accept symptoms for triage, or provide a medical opinion on any individual situation. Readers looking for medical advice should consult a licensed clinician in their jurisdiction. Readers looking to purchase ipamorelin in the United States should know that, as of late 2024, there is no FDA-sanctioned compounding pathway for the substance [5][6], and that the gray-market supply channel has documented systematic quality failures [14]. Those facts are part of the published record and are reported on this site for completeness; they are not a recommendation about what to do with them. ## Sourcing methodology Citations on this site are drawn from indexed peer-reviewed journals (European Journal of Endocrinology, Pharmaceutical Research, International Journal of Colorectal Disease, Growth Hormone and IGF Research, British Journal of Pharmacology, Toxicologic Pathology, Endocrine-Related Cancer, JCSM Rapid Communications, Journal of Neurogastroenterology and Motility, Physiology and Behavior, Neuroendocrinology Letters), from ClinicalTrials.gov for registered trial records, from the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee materials, and from the World Anti-Doping Agency Prohibited List. Where regulatory documents are referenced through secondary legal or news coverage, the original FDA source is also cited. The aim is that every claim is traceable to a primary or near-primary source that a reader can verify. ## References [1] Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. [2] Gobburu JV et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. [3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Phase 2 ipamorelin RCT in postoperative ileus. International Journal of Colorectal Disease. 2014;29(12):1527-1534. [5] U.S. FDA. PCAC Briefing Document (October 29, 2024) — Ipamorelin Acetate / free base review for 503A. 2024. [6] U.S. FDA / Lexology / Holt Law summaries. FDA Briefing Document on Ipamorelin — aggregation, immunogenicity, unnatural amino acids. 2024. [14] Preventive Medicine Daily editorial / pharmacovigilance review. Gray-Market Peptides from China. 2024. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor. --- # Contact — Ipamorelin Safe editorial > Reach the Ipamorelin Safe editorial desk with citation corrections, fact-check notes, or feedback on the safety reading. Not medical advice. Does not sell any product. Citation corrections, fact-check notes, and feedback on the safety reading are welcome. Medical questions are not. ## What to write to us about The editorial desk welcomes the following kinds of correspondence. **Citation corrections** — if a study referenced on the site has been retracted, superseded, or misattributed, the editors want to know. **Fact-check notes** — if a claim on the site is not adequately supported by its cited reference, please point to the page, the bracketed citation number, and the disputed sentence. **New literature** — if a peer-reviewed paper on ipamorelin has been published that materially changes the safety reading, a pointer with the DOI is welcome. **Editorial feedback** — if a section of the site reads as misleading, slanted, or evasive on a safety question, that is exactly the kind of note that improves the ledger. ## What this contact form is not for The editorial desk cannot answer medical questions. The editors are not clinicians; the publication is not a clinic; no individual medical advice will be provided regardless of how the question is framed. The desk cannot provide dosing guidance for any human use of ipamorelin. The desk cannot recommend a vendor, a clinic, a compounding pharmacy, or a research-chemical supplier. The publication does not sell ipamorelin or any other product, and it is not affiliated with any vendor or manufacturer. Inquiries on these topics will not receive a substantive reply; please consult a licensed clinician in your jurisdiction instead. ## Contact form Use the form at https://ipamorelinsafe.com/contact to reach the editorial desk. Please include the page URL and the bracketed citation number when relevant; the desk is small and the more precisely a note is framed, the faster it can be addressed. Submissions route to the editorial mailbox; the desk aims to acknowledge correspondence within a small number of business days. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.